Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study

ConclusionDotinurad has a substantial serum uric acid lowering effect in patients with hyperuricemia. No serious adverse event was found.ClinicalTrials.gov IdentifierNCT02344862
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research